GSK Pharma reported better than expected PAT on lower raw material cost and increased benefit from marketing activities, along with high demand for vaccines.
GSK Pharma reported better than expected PAT on lower raw material cost and increased benefit from marketing activities, along with high demand for vaccines. GSK Pharma reported better than expected PAT on lower raw material cost and increased benefit from marketing activities, along with high demand for vaccines. Moneycontrol Latest News Read More
English 
हिन्दी